B
Bella Kaufman
Researcher at Sheba Medical Center
Publications - 202
Citations - 20598
Bella Kaufman is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 56, co-authored 200 publications receiving 16869 citations. Previous affiliations of Bella Kaufman include Tel Aviv University & Peter MacCallum Cancer Centre.
Papers
More filters
Journal ArticleDOI
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer,John K. Forster,Deborah Lindquist,Stephen Chan,C. Gilles Romieu,Tadeusz Pienkowski,Agnieszka Jagiełło-Gruszfeld,John Crown,Arlene Chan,Bella Kaufman,Dimosthenis Skarlos,Mario Campone,Neville Davidson,Mark S. Berger,Cristina Oliva,Stephen D. Rubin,S. Stein,David Cameron +17 more
TL;DR: Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.
Journal ArticleDOI
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fatima Cardoso,Ana Costa,Elżbieta Senkus,Matti Aapro,Fabrice Andre,Carlos H. Barrios,Jonas Bergh,G. Bhattacharyya,Laura Biganzoli,Maria João Cardoso,Lisa A. Carey,D. Corneliussen-James,Giuseppe Curigliano,Véronique Diéras,N.S. El Saghir,Alex Eniu,Lesley Fallowfield,D. Fenech,Prudence A. Francis,Karen A. Gelmon,Alessandra Gennari,Nadia Harbeck,Clifford A. Hudis,Bella Kaufman,Ian E. Krop,Musa Mayer,H. Meijer,Shirley Mertz,S. Ohno,Olivia Pagani,E. Papadopoulos,Fedro A. Peccatori,Frédérique Penault-Llorca,Martine Piccart,Jean-Yves Pierga,Hope S. Rugo,Lillie D. Shockney,George W. Sledge,Sandra M Swain,Christoph Thomssen,Andrew Tutt,Daniel A. Vorobiof,Binghe Xu,Larry Norton,Eric P. Winer +44 more
TL;DR: This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients, and provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care.
Journal ArticleDOI
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman,Ronnie Shapira-Frommer,Rita K. Schmutzler,M. William Audeh,Michael Friedlander,Judith Balmaña,Gillian Mitchell,Georgeta Fried,Salomon M. Stemmer,Ayala Hubert,Ora Rosengarten,Mariana Steiner,Niklas Loman,Karin Bowen,Anitra Fielding,Susan M. Domchek +15 more
TL;DR: Responses to olaparib were observed across different tumor types associated with germline BRCA1/2 mutations, and warrants further investigation in confirmatory studies.
Journal ArticleDOI
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Deborah Nejman,Ilana Livyatan,Garold Fuks,Nancy Gavert,Yaara Zwang,Leore T. Geller,Aviva Rotter-Maskowitz,Roi Weiser,Roi Weiser,Giuseppe Mallel,Elinor Gigi,Arnon Meltser,Gavin M. Douglas,Iris Kamer,Vancheswaran Gopalakrishnan,Tali Dadosh,Smadar Levin-Zaidman,Sofia Avnet,Tehila Atlan,Zachary A. Cooper,Reetakshi Arora,Alexandria P. Cogdill,Abdul Wadud Khan,Gabriel Ologun,Yuval Bussi,Adina Weinberger,Maya Lotan-Pompan,Ofra Golani,Gili Perry,Merav Rokah,Keren Bahar-Shany,Elisa A. Rozeman,Christian U. Blank,Anat Ronai,Ron Shaoul,Amnon Amit,Amnon Amit,Tatiana Dorfman,Ran Kremer,Zvi R. Cohen,Zvi R. Cohen,Sagi Harnof,Sagi Harnof,Tali Siegal,Einav Yehuda-Shnaidman,Einav Nili Gal-Yam,Hagit Shapira,Nicola Baldini,Morgan G. I. Langille,Alon Ben-Nun,Alon Ben-Nun,Bella Kaufman,Bella Kaufman,Aviram Nissan,Talia Golan,Talia Golan,Maya Dadiani,Keren Levanon,Keren Levanon,Jair Bar,Jair Bar,Shlomit Yust-Katz,Shlomit Yust-Katz,Iris Barshack,Iris Barshack,Daniel S. Peeper,Dan J. Raz,Eran Segal,Jennifer A. Wargo,Judith Sandbank,Noam Shental,Ravid Straussman +71 more
TL;DR: A comprehensive analysis of the tumor microbiome was undertaken, studying 1526 tumors and their adjacent normal tissues across seven cancer types, finding that each tumor type has a distinct microbiome composition and that breast cancer has a particularly rich and diverse microbiome.
Journal ArticleDOI
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron,Michelle Casey,Michael F. Press,Deborah Lindquist,Tadeusz Pienkowski,C. Gilles Romieu,Stephen Chan,Agnieszka Jagiełło-Gruszfeld,Bella Kaufman,John Crown,Arlene Chan,Mario Campone,Patrice Viens,Neville Davidson,Veira Gorbounova,Johannes Isaac Raats,Dimosthenis Skarlos,B. Newstat,Debasish F. Roychowdhury,Paolo Paoletti,Cristina Oliva,Stephen D. Rubin,S. Stein,Charles E. Geyer +23 more
TL;DR: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy.